At 3 months after treatment, use of healthcare or social services was also lower in the molnupiravir group at 14.1% versus 15 ...

Molnupiravir treatment for COVID-19 shows modest long-term benefits, reducing symptoms and improving well-being at three and ...

Molnupiravir has shown to be a promising option for treating feline infectious peritonitis as a first- and second-line ...

Wedgewood, the nation’s largest provider of compounded veterinary medications, announces the addition of molnupiravir to its ...

Today, Wedgewood announces the addition of molnupiravir to its formulary. Originally developed for human viral infections, including COVID-19, molnupiravir has emerged as a promising option for ...

New research has found that molnupiravir offers modest longer term benefits to vaccinated adults. This is the latest outcome of the NIHR funded and delivered PANORAMIC trial, led by the University of ...

Researchers indicate that the vaccine and booster shots should protect against the new variant. Here is what we know about ...

A new COVID variant, XEC, has arrived just before fall. The new variant has sprouted from the Omicron variant that developed ...